H M Horton

Summary

Affiliation: Vical Incorporated
Country: USA

Publications

  1. ncbi DNA vaccines for cancer therapy
    - Horton
    Vical, Inc, San Diego, CA 92121, USA
    Expert Opin Investig Drugs 8:2017-2026. 1999
  2. pmc A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha
    H M Horton
    Vical, Inc, 9373 Towne Centre Drive, Suite 100, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 96:1553-8. 1999
  3. ncbi Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice
    H M Horton
    Vical, Inc, San Diego, California 92121, USA
    Cancer Res 59:4064-8. 1999
  4. ncbi IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
    H M Horton
    Vical, Inc, San Diego, CA 92121, USA
    J Immunol 163:6378-85. 1999

Collaborators

  • - Horton
  • - Norman
  • - Wloch
  • - Parker

Detail Information

Publications4

  1. ncbi DNA vaccines for cancer therapy
    - Horton
    Vical, Inc, San Diego, CA 92121, USA
    Expert Opin Investig Drugs 8:2017-2026. 1999
    ..With advances in modern genomics strategies and the identification of an increasing number of tumour antigen genes, pDNA-based cancer vaccines may be used in the future to treat a wide variety of human cancers...
  2. pmc A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha
    H M Horton
    Vical, Inc, 9373 Towne Centre Drive, Suite 100, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 96:1553-8. 1999
    ..These studies demonstrate that primary and metastatic tumors can be treated systemically by i.m. injection of a plasmid encoding a cytokine gene...
  3. ncbi Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice
    H M Horton
    Vical, Inc, San Diego, California 92121, USA
    Cancer Res 59:4064-8. 1999
    ..009). These results demonstrate for the first time that IFN-omega can have in vivo antitumor effects in several models of human cancer...
  4. ncbi IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
    H M Horton
    Vical, Inc, San Diego, CA 92121, USA
    J Immunol 163:6378-85. 1999
    ..p. treatment of ovarian tumors with IL-2 pDNA:DMRIE/DOPE can lead to an increase in local IL-2 levels, a change in the cytokine profile of the tumor ascites, and a significant antitumor effect...